Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Phase 2 N=70 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Tumor · Breast Cancer
Primary: Objective Response Rate (ORR) — 28.6; 35 percentage of subjects
Phase 2 N=29 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Phase 2 N=40 Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response. — 41 percentage of evaluable patients
Phase 2 N=160 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Phase 2 N=140 MEtronomic TrEatment Option in Advanced bReast cAncer
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Phase 2 N=43 BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Breast Cancer
Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 2 N=32 Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 16 Months
Phase 4 N=70 A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Primary: Severity of Adverse Events — 53; 40; 18; 2 Participants
Phase 2 N=12 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Estrogen Receptor-negative Breast Cancer · Male Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Disease Control Rate (DCR) — 0 participants
Phase 2 N=19 Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Estrogen Receptor Positive · Male Breast Carcinoma · Progesterone Receptor Positive
Primary: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 1 participants
Phase 3 N=1,102 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Metastatic Breast Cancer
Primary: Overall Survival (OS) — 484; 440 days
Phase 2 N=187 A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 0.489; 0.587 proportion of responders — p=0.117
Phase 3 N=608 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Breast Cancer
Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…
Phase 2 N=32 Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
Invasive Breast Cancer
Primary: Rate of Achievement of Pathological Complete Response (pCR) — 9 pathology specimens from participants
Phase 2 N=52 Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Time — 4.80 months
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=31 Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
Breast Cancer
Primary: Median Time to Progression — 149 Days
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=56 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response Following Principle Investigator Review — 23.2 percentage of participants
Phase 2 N=217 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Phase 2 N=215 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=55 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Breast Cancer
Primary: Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab — 300; 300 mg
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants